Description
Basic introduction
Tirzepatide is a synthetic peptide investigated through both GIP and GLP-1 receptor pathways. Its structure includes a lipid modification, which is relevant to the pharmacological preparation described in the scientific literature.
The research spans receptor assays, animal models and clinical studies. These evidence levels should remain separate: a receptor response characterizes one aspect of a molecule, while a clinical study concerns a defined formulation, population and protocol.
Mechanism of action · Research context
GIP receptor response
Tirzepatide was characterized as a GIP receptor agonist. Receptor-specific assays help define this activity independently of its response at the GLP-1 receptor.
GLP-1 receptor response
GLP-1 receptor activity provides a second experimental pathway. Comparing signaling in matched assay systems is more informative than assuming equal activity at both receptors from the dual-agonist label alone.
Integrated metabolic effects
Whole-system responses involve more than receptor activation. The discovery program examined glucose-dependent insulin secretion and metabolic outcomes across several experimental settings.
Extended research considerations
Receptor assay controls
Identify the receptor expression system and readout. Differences in receptor abundance, assay timing or signal amplification can affect comparisons between GIP and GLP-1 responses.
Formulation and exposure
Lipid modification influences the tested preparation. Analytical identity, aggregation and compatibility with the assay medium are separate from the receptor-response result.
Clinical evidence context
Clinical trials evaluate specific pharmaceutical preparations. Their outcomes do not certify the identity, sterility or clinical suitability of a research product sold independently of those studies.
Material and packaging
Available kit specifications: 5 mg × 10 vials; 10 mg × 10 vials; 15 mg × 10 vials; 20 mg × 10 vials; 30 mg × 10 vials; 40 mg × 10 vials; 50 mg × 10 vials; 60 mg × 10 vials; 100 mg × 10 vials; 120 mg × 10 vials. Select an option above to view its current price and availability.
Storage and handling
Source-listed storage condition: Store at 20°C to 25°C (Do not freeze). Follow the handling instructions supplied with the actual batch and your laboratory's procedures.
Analytical documentation
Reference analytical documents are available with this listing. Check the material identity, batch number and test date against the batch supplied; contact us for current batch documentation.
Scientific references
These publications describe the studied molecules and experimental models. They do not certify the identity, quality or effects of a particular supplied batch.
- Discovery and experimental characterization of LY3298176
- Phase 2 tirzepatide clinical research
View report
View report
Milo Hale –
I run blood sugar and weight-related lab tests, TR10 delivers far more stable data than cheap peptide brands. Its over 99% purity stops unknown impurities from messing up my test numbers. I store bottles at regular room temperature, freezing a vial by mistake once erased most of its active effects. Mixed liquid stays clear for 5 days refrigerated, perfectly matching my weekly mouse injection plan.
Iris Sloan –
The standard 10mg vial fits my weekly fat-loss mouse trials perfectly. Powder dissolves fully without sticky residue on glass walls. I reordered three bulk kits, every batch acts exactly the same. Multiple vial sizes let me finish all dose tests without switching suppliers.
Gideon A. –
I have tested Tirzepatide from multiple suppliers, and this buffered batch delivers much better stability. The powder remains bright white straight out of the vial and dissolves easily with gentle swirling without damaging the peptide chain.
Jett Ross –
Bright lab lights quickly weaken this peptide’s activity. After I moved all TR10 stock into dark storage cabinets, my test results became much more consistent. Other brands never clearly remind users about light damage.
Rainer Rowe –
I stored sealed TR10 vials inside dark 22°C constant-temperature cabinets for two full months, the white lyophilized powder stayed bright white with zero yellow discoloration or clumping. Follow-up adipocyte testing confirmed its fat breakdown and glucose-lowering biological activity matched fresh new stock completely. My previous Tirzepatide supplier’s product faded yellow and lost over half its potency after just three weeks of room-temperature storage.